We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Edgewise Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for EDG-5506 to treat Duchenne muscular dystrophy. EDG-5506 is an investigational orally
ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer, today announced an oversubscribed $112 million Series B financing supported by a syndicate of top
BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series
Takeda has received approval from the US Food and Drug Administration (FDA) for Eohilia (budesonide oral suspension) as oral treatment in people 11 years and older with eosinophilic
Biogen has secured the European Commission (EC) approval for Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA) in adults and adolescents of age 16 years and older. Skyclarys is
Saama has expanded its multi-year agreement with Pfizer to integrate artificial intelligence (AI)-based data solutions across the latter’s research and development (R&D) portfolio. Based in California, Saama provides
GSK announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic
AbbVie announced today that it has completed its acquisition of ImmunoGen. With the completion of the acquisition, ImmunoGen is now part of AbbVie. “Together with ImmunoGen, we have
Johnson & Johnson (J&J) has secured breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for nipocalimab to treat alloimmunised pregnant individuals at increased risk
Hemab Therapeutics said that its bispecific antibody HMB-001 was well tolerated in the ongoing Phase 1/2 trial of patients with bleeding disorder Glanzmann Thrombasthenia. HMB-001 is engineered to